Description: Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.
Home Page: www.evaxion-biotech.com
EVAX Technical Analysis
Dr. Neergaards Vej
Horsholm,
2970
Denmark
Phone:
45 53 53 18 50
Officers
| Name | Title |
|---|---|
| Dr. Niels Iversen Moeller M.D. | Co-Founder, VP of Bus. & Director |
| Mr. Andreas Holm Mattsson | Co-Founder and Chief AI & Culture Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
| Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Per Norlen | Chief Exec. Officer |
| Mr. Bo Lokke Karmark | Chief Financial Officer |
| Mr. Jesper Nyegaard Nissen | Chief Operating Officer |
| Dr. Jürgen Langhärig EMBA, Ph.D. | Head of Bus. Devel. & Member of Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.8052 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 70 |